Rubicon Healthcare Partners is pleased to announce that it has led a $20 million financing round in Moleculent AB, a Stockholm-based life sciences technology company pioneering functional profiling — a new approach to mapping how cells communicate within intact human tissue. The round was completed alongside ARCH Venture Partners and Eir Ventures. As part of the investment, Rubicon Managing Partner Ole Dahlberg has joined the Moleculent Board of Directors. The capital will support expansion of Moleculent's Techstart Early Access Program, accelerate US commercial operations, and advance preparations for commercial launch. Moleculent's platform addresses a fundamental gap in spatial biology and represents the type of category-defining life science tools company at the core of Rubicon's investment strategy.

ClinStorage has established itself as a trusted partner to pharmaceutical and biotechnology companies by providing secure, regulatory-compliant storage and handling of clinical trial materials. The transaction provides ClinStorage with growth capital and sector-focused ownership to support continued investments in infrastructure, capacity, and service capabilities - while maintaining the quality, compliance, and reliability that define the company’s offering.

Jonas Brambeck brings more than 25 years of experience in life science investing, company building, and strategic transactions. As Industry Advisor, Jonas will support Rubicon in investment evaluation, strategic development of portfolio companies, and engagement with key stakeholders across the Nordic life science ecosystem.

Through this investment, Rubicon will become the largest shareholder in PeptiSystems following completion of the transaction. The partnership reflects Rubicon’s strategy of supporting high-quality Nordic life science platforms with strong technology foundations, scalable business models, and global market potential.